Compugen

Compugen is a clinical-stage drug-discovery and development company with a broadly applicable predictive-discovery infrastructure that is advancing a therapeutic pipeline consisting mainly of early-stage immuno-oncology programs aimed at harnessing the immune system to eradicate cancer. The company's pipeline is based on novel Compugen-discovered drug targets, primarily immune checkpoint candidates that are predicted to provide cancer immunotherapies addressing unmet cancer types and patient populations, both as monotherapies and in combination. In 2010, Compugen chose to specialize in oncology and immunology, with a focus on immuno-oncology. Compugen's first application of its predictive discovery infrastructure was in the field of immune checkpoints, with the goal of developing novel, effective cancer immunotherapies. The company has also expanded its discovery capabilities to include myeloid target candidates within the tumor microenvironment. Today, Compugen's pipeline includes multiple opportunities for therapeutics addressing areas of unmet medical need in the field of oncology.

Compugen has raised $141.92M in total funding across 7 rounds. The company is currently at the Public stage. Key investors include Bristol-Myers Squibb Company, GlobalServe, Bayer HealthCare.

Compugen operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, Drug Delivery, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients.

Compugen is based in Harokmim 26, Holon, Israel, Center District. The company also has offices abroad.